Multiple Myeloma in 2022 and Beyond
Clinical experts from the US discuss current treatment strategies and emerging therapies, including MRD, IMiDs, proteasome inhibitors, and immunotherapy approaches
September 23 and 24, 2022
Faculty Chair
Rafael Fonseca, MD
Mayo Clinic, Phoenix, AZ, USA
Faculty Members
Leif Bergsagel, MD, FASCO
Mayo Clinic, Phoenix, AZ, USA
Saurabh Chhabra, MBBS, MD
Mayo Clinic, Phoenix, AZ, USA
Andrzej Jakubowiak, MD, PhD
University of Chicago, IL, USA
Ajai Chari, MD
Mount Sinai New York, NY, USA
Gareth Morgan, MD, PhD, FRCP, FRCPath
Perlmutter Cancer Center, New York, NY, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Frontline Transplant-Eligible MM
- Frontline Transplant-Ineligible MM
- MRD, Maintenance, and Consolidation Update
- The Continued Role of Immunomodulatory Agents (IMiDs) and Proteasome Inhibitors (PIs)
- Next-Generation Small Molecules: BCL2, XPO1, BCMA Inhibitors, and Beyond
- CAR T Therapies for the Treatment of MM
- Bispecific Agents for the Treatment of MM
